1-(2-Bromo-ethoxy)-4-((Z)-1,2-diphenyl-but-1-enyl)-benzene | 73237-46-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 1-(2-Bromo-ethoxy)-4-((Z)-1,2-diphenyl-but-1-enyl)-benzene
• 英文别名: 1-(2-bromoethoxy)-4-[(Z)-1,2-diphenylbut-1-enyl]benzene
• CAS: 73237-46-4
• 化学式: C₂₄H₂₃BrO
• 分子量: 407.35
• InChiKey: SESDRMKQMZBTML-VHXPQNKSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.83
• 重原子数：
  26.0
• 可旋转键数：
  7.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  9.23
• 氢给体数：
  0.0
• 氢受体数：
  1.0

反应信息

• 作为反应物：
  描述：

  1-(2-Bromo-ethoxy)-4-((Z)-1,2-diphenyl-but-1-enyl)-benzene 在 三乙烯二胺 、 正丁基锂 、 sodium iodide 、 碘甲烷 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 32.5h， 生成 (Z)-1,2-diphenyl-1-<4-<3-(N-pyrrolidino)propoxy>phenyl>-1-butene
  参考文献：
  名称：

  Antiestrogen basicity-activity relationships: a comparison of the estrogen receptor binding and antiuterotrophic potencies of several analogs of (Z)-1,2-diphenyl-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-butene (Tamoxifen, Nolvadex) having altered basicity

  摘要：

  A series of N-substituted (Z)-1,2-diphenyl-1-[4-(2-aminoethoxy)phenyl]-1-butenes, analogues of the antiestrogen tamoxifen (Nolvadex), in which the side-chain basicity is varied over a wide range, has been prepared to probe the importance of basicity in evoking estrogen antagonism. All of the compounds, except the pyrrole analogue 14, were found to possess significant antiestrogenic activity in the rat, as measured by their ability to inhibit estrogen-induced uterine growth. This implies that in the tamoxifen series the level of side-chain basicity, at least in the Lowry-Brønsted sense, is not a determining factor in the estrogen antagonist potencies of these compounds.

  DOI：

  10.1021/jm00344a015
• 作为产物：
  描述：

  [4-(2-溴乙氧基)苯基]-苯基甲酮 、 苯丙酮 、 三氯化钛 生成 1-(2-Bromo-ethoxy)-4-((Z)-1,2-diphenyl-but-1-enyl)-benzene
  参考文献：
  名称：

  COE, P. L.;SCRIVEN, C. E., J. CHEM. SOC. PERKIN TRANS., 1986, N 3, 475-477

  摘要：

  DOI：

文献信息

• Preparation of tamoxifen
  申请人：NATIONAL RESEARCH DEVELOPMENT CORPORATION

  公开号：EP0168175B1

  公开（公告）日：1987-11-19
• ROBERTSON, D. W.;KATZENELLENBOGEN, J. A.;HAYES, J. R.;KATZENELLENBOGEN, B+, J. MED. CHEM., 1982, 25, N 2, 167-171
  作者：ROBERTSON, D. W.、KATZENELLENBOGEN, J. A.、HAYES, J. R.、KATZENELLENBOGEN, B+

  DOI：——

  日期：——
• USE OF TRIPHENYLBUTENE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
  申请人：AstraZeneca AB

  公开号：EP1127045A2

  公开（公告）日：2001-08-29
• US6489481B1
  申请人：——

  公开号：US6489481B1

  公开（公告）日：2002-12-03
• [EN] NEUROLOGICAL DISORDERS<br/>[FR] TROUBLES NEUROLOGIQUES
  申请人：ZENECA LTD

  公开号：WO2000025767A2

  公开（公告）日：2000-05-11

  The use of a compound of Formula (VIII) in the manufacture of a medicament for the treatment of or the prevention of neurological disorders, in a warm-blooded mammal, wherein A and B are selected from: Formula (IX) or Formula (X) such that when A is of Formula (X) then B is of Formula (IX) and when A is of Formula (IX) then B is of Formula (X). R1 is selected from hydrogen, halo, aryl, carbamoyl, N-C1-4alkylcarbamoyl or NN-di-C1-4alkylcarbamoyl; D is selected from C1-4alkylene, C1-4alkenylene or alkynylene; R2 is selected from hydrogen, C1-4alkyl or hydroxy; R3 is selected from hydrogen, hydroxy, halo, PO4, C1-4alkoxy, or a group of the formula: -E-F-G-H wherein: E is selected from: (a), (b), (c), (d), (e), or (f); F is selected from: (a), (b), or a direct bond; G is selected from C1-6alkyl, or a direct bond; H is selected from hydrogen, C1-4alkoxy, or optionally substituted aryl; heteroaryl, or carbocyclyl; R4 and R5 are independently selected from methyl, ethyl or phenyl, or together with the nitrogen atom to which they are attached form a ring selected from pyrrolidine, piperidine or morpholine; R6 is selected from hydrogen, C1-4alkyl; C1-4alkoxy, halo, or a ring fused phenyl group fused via carbons 3 and 4 on the phenyl group of Formula (X); R7 and R8 are either both hydrogen or when A is of Formula (X) may be joined either via a sulphur atom, via -CH2- or via -C2H4; R9 is selected from hydrogen or C1-4alkyl; and n is 2 or 3; or a pharmaceutically acceptable salt, prodrug or solvate thereof. Processes for their preparation of compounds of Formula (VIII) are described, as are compositions containing them and their use.